Rationale: In clinical practice, the investigators see that ADHD affects women
differently than men. It has become clear that a better understanding of ADHD in girls
and women is needed to improve their longer-term wellbeing and functional and clinical
outcomes.
Objective: The primary endpoint is to describe the overall experience of women with ADHD
regarding ADHD symptoms, diagnosis, treatment, and any perceived barriers relating to
these domains. The investigators also want to determine the effects of ADHD symptoms on
day-to-day life across various life domains. Moreover, the investigators want to
determine the prevalence of reported health conditions.
Study design: This is an exploratory study following a cross-sectional online survey.
Study population: Women (aged >18 years) with ADHD.
Intervention (if applicable): Not applicable.
Main study parameters/endpoints: In women with ADHD, the investigators want to 1)
describe overall experiences regarding ADHD symptoms, diagnosis, treatment, sources of
support, and any perceived barriers on those domains; 2) determine which life domains are
most affected by ADHD symptoms; 3) calculate the prevalence of reported health conditions
within the following domains: circulatory system, endocrine or metabolic system,
gastrointestinal system, genitourinary system, musculoskeletal system, nervous system,
respiratory system, skin, reproductive system, cancer, psychiatric conditions, COVID-19,
sensory sensitivity, menstrual cycle, and sleep; 4) identify topics that women with ADHD
would like to see studied in future research.
Nature and extent of the burden and risks associated with participation, benefit and
group relatedness: This survey is the first to study experiences and health of women with
ADHD internationally, and results will provide insights and leads for all involved with
diagnosis and treatment of these women. Risks of participation are considered low.
Participants might consider certain questions triggering, but are always free to skip
questions and stop the survey.